CASTLE BIOSCIENCES Q3 2025 TL;DR
Financial Performance & Profitability Reversal: For the nine months ended September 30, 2025, revenue grew modestly to $257.2M (up from $245.8M in 2024), but the company swung to a $21.8M Net Loss (vs. $8.7M Income prior year), resulting in a Basic/Diluted EPS of $(0.76). Q3 revenue declined 3.2% to $83.0M, reporting a net loss of ($0.5M) against a $2.3M profit in Q3 2024. The Gross Margin plummeted to 66.8% (from 79.3%) following the loss of Medicare LCD coverage for DecisionDx-SCC.
Key Expense & Investment Drivers: A massive surge in
...